- Home
- APM vs RNAZ Comparison
APM vs RNAZ Comparison
Compare APM & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APM | RNAZ |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 8.5M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | APM | RNAZ |
|---|---|---|
| Price | $0.80 | $9.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $280.00 |
| AVG Volume (30 Days) | ★ 21.9K | 11.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.65 | $0.22 |
| 52 Week High | $4.47 | $20.99 |
Technical Indicators
Market Signals| Indicator | APM | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 43.33 | 51.24 |
| Support Level | $0.74 | $9.67 |
| Resistance Level | $1.11 | $11.79 |
| Average True Range (ATR) | 0.05 | 0.71 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 34.58 | 60.05 |
Price Performance
Historical ComparisonAbout APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.